Unlock Premium for Just $9.99/Month – Special Launch Offer, Limited Time Only
Get Premium
ELTX Elicio Therapeutics Inc.
- Stocks
- Healthcare
- NASDAQ: ELTX
Price (delayed)
$8.42
Market cap
$134.69M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$3.92
Enterprise value
$121.45M
Highlights
ELTX's equity has surged by 179% since the previous quarter and by 83% year-on-year
ELTX's debt has shrunk by 78% QoQ and by 13% YoY
The quick ratio has decreased by 20% YoY but it has increased by 2.5% QoQ
The net income has declined by 32% year-on-year
Key stats
What are the main financial stats of ELTX
Market
Valuations
Earnings
Shares outstanding
16M
Market cap
$134.69M
Enterprise value
$121.45M
Price to earnings (P/E)
N/A
Price to book (P/B)
15.09
Price to sales (P/S)
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Revenue
$0
Gross profit
$0
Operating income
-$45.48M
Net income
-$51.28M
EBIT
-$50.68M
EBITDA
-$49.52M
Free cash flow
-$35.15M
Per share
Balance sheet
Liquidity
EPS
-$3.92
EPS diluted
-$3.92
Free cash flow per share
-$2.71
Book value per share
$0.56
Revenue per share
$0
TBVPS
$2.17
Total assets
$28.14M
Total liabilities
$19.24M
Debt
$5.79M
Equity
$8.9M
Working capital
$9.52M
Debt to equity
0.65
Current ratio
1.83
Quick ratio
1.67
Net debt/EBITDA
0.27
Margins
Efficiency
Dividend
EBITDA margin
N/A
Gross margin
N/A
Net margin
N/A
Operating margin
N/A
Return on assets
-185.7%
Return on equity
N/A
Return on invested capital
-306.1%
Return on capital employed
-302.9%
Return on sales
N/A
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
ELTX stock price
How has the Elicio Therapeutics stock price performed over time
Intraday
-0.94%
1 week
9.07%
1 month
7.54%
1 year
125.13%
YTD
65.1%
QTD
9.07%
Financial performance
How have Elicio Therapeutics's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$45.48M
Net income
-$51.28M
Gross margin
N/A
Net margin
N/A
The net income has declined by 32% year-on-year
The operating income has declined by 19% year-on-year
Price vs fundamentals
How does ELTX's price correlate with its fundamentals
Growth
What is Elicio Therapeutics's growth rate over time
Valuation
What is Elicio Therapeutics stock price valuation
P/E
N/A
P/B
15.09
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Elicio Therapeutics's EPS has increased by 25% YoY and by 8% from the previous quarter
ELTX's equity has surged by 179% since the previous quarter and by 83% year-on-year
Efficiency
How efficient is Elicio Therapeutics business performance
The company's return on assets fell by 43% YoY but it rose by 4.5% QoQ
ELTX's return on invested capital is down by 12% since the previous quarter
Dividends
What is ELTX's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for ELTX.
Financial health
How did Elicio Therapeutics financials performed over time
The total assets is 46% greater than the total liabilities
ELTX's total liabilities has shrunk by 51% QoQ
The current ratio has contracted by 23% YoY
ELTX's debt is 35% lower than its equity
ELTX's equity has surged by 179% since the previous quarter and by 83% year-on-year
Elicio Therapeutics's debt to equity has soared by 128% from the previous quarter but it has plunged by 53% YoY
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.